Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P648: The impact of infliximab therapeutic drug monitoring on decisions made in a virtual biologics clinic for IBDECCO '17 Barcelona
Year: 2017
Authors:

Selinger C.*1, Lenti M.1, Clark T.1, Rafferty H.1, O'Connor A.1, Ahmad T.2, Hamlin J.1

1St James University Hospital, Gastroenterology, Leeds, United Kingdom 2Royal Devon & Exeter Foundation Trust, Gastroenterology, Exeter, United Kingdom

P649: Does switching to low dose thiopurine and allopurinol prevent IBD patients with evidence of hypermethylation on standard dose thiopurines from developing hepatotoxicity and drug side effects?ECCO '17 Barcelona
Year: 2017
Authors:

Wade K., Johnson H., Slinger K., Hovell C., Weaver S., McLaughlin S.

Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, United Kingdom

P650: The prognostic impact of radical resection margins on the Recurrence of Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

van Amesfoort J.*1, Koens L.2, Bemelman W.1, Buskens C.1

1Academical Medical Centre, Surgery, Amsterdam, Netherlands 2Academical Medical Centre, Pathology, Amsterdam, Netherlands

P651: Barriers to clinical research in children with inflammatory bowel disease: the patients' perspectiveECCO '17 Barcelona
Year: 2017
Authors:

El-Matary W., Deora V.

University of Manitoba, Department of Paediatrics, Winnipeg, Canada

P652: Unmet needs of physicians managing inflammatory bowel disease. A Survey of the Italian Group for Inflammatory Bowel Disease (IG-IBD)ECCO '17 Barcelona
Year: 2017
Authors:

Saibeni S.*1, Bezzio C.1, Armuzzi A.2, Bossa F.3, Calabrese E.4, Caprioli F.5, Daperno M.6, Mocciaro F.7, Orlando A.8, Papi C.9, Rispo A.10, Rizzello F.11 IG-IBD

1ASST Rhodense, Gastroenterology Unit, Rho, Italy 2Policlinico Gemelli, Rome, Italy 3Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy 4Policlinico Tor Vergata, Rome, Italy 5University of Milan, Milan, Italy 6Ospedale Mauriziano, Torino, Italy 7Ospedale Arnas Civico, Palermo, Italy 8Ospedale Cervello, Palermo, Italy 9Ospedale San Filippo Neri, Rome, Italy 10Policlinico Federico II, Naples, Italy 11University of Bologna, Bologna, Italy

P653: The efficacy and safety of stem cell therapy for Crohn's disease: a meta-analysisECCO '17 Barcelona
Year: 2017
Authors:

Qiu Y.*1, Zhang S.-h.2, Mao R.1, Feng R.2, Zeng Z.-r.1, Chen M.-h.2

1The first affiliated hospital of Sun-yat Sen University, Gastroenterology, Guangzhou, China 2The first affiliated hospital of Sun-yat Sen University, Guangzhou, China

P654: Mucosal healing with a second anti-TNF-α in patients with ulcerative colitis after the failure of the previous anti-TNF-α treatmentECCO '17 Barcelona
Year: 2017
Authors:

Papa A., Pugliese D., D'Aversa F., De Vitis I., Landi R., Guidi L., Felice C., Gerardi V., Armuzzi A., Gasbarrini A., Rapaccini G.L.

Catholic University of Rome, Fondazione Policlinico Gemelli, Internal Medicine and Gastroenterology, Roma, Italy

P655: A study to determine factors affecting clinical decision making in outpatients with inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Derwa Y.1, Gracie D.J.*1,2, Williams C.J.1, Sood R.1,2, Mumtaz S.1, Bholah M.H.1, Hamlin P.J.1, Ford A.C.1,2

1St. James's University Hospital, Leeds Gastroenterology Institute, Leeds, United Kingdom 2University of Leeds, LIBACS, Leeds, United Kingdom

P656: Is there a role for additional oral mesalamine therapy in the treatment of ulcerative proctitis with skip inflammation?ECCO '17 Barcelona
Year: 2017
Authors:

Choi Y.S.*1, Kim W.J.1, Kim J.K.1, Song K.-H.2, Jung H.-J.2

1Daehang Hospital, Gastroenterology, Seoul, South Korea 2Daehang Hospital, Surgery, Seoul, South Korea

P657: The predictors and clinical outcomes of follow up loss of clinics in patients with inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Kim K.O.1, Jang B.I.1, Koo E.J.*1, Kang M.K.1, Yang C.H.2

1Yeungnam University College of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Daegu, South Korea 2Dongguk University College of Medicine, Division of gastroenterology and Hepatology, department of Internal Medicine, Kyungju, Korea, Republic of

P658: The Inflammatory Bowel Disease Disability Index (IBD-DI) in ulcerative colitis is related to disease activity, need of immunosuppressive therapy and quality of lifeECCO '17 Barcelona
Year: 2017
Authors:

Morreale G.C., Calvaruso V., Sanfratello A., Cappello M.

Policlinico Paolo Giaccone, Gastroenterology Section, DiBiMis, University of Palermo, Italy, Palermo, Italy

P659: Therapeutic drug monitoring of anti-TNFα drugs in a UK tertiary IBD unitECCO '17 Barcelona
Year: 2017
Authors:

Barrow V.*1, Innes A.1, Thompson N.1, Mansfield J.1,2, Speight A.1,3

1Newcastle upon Tyne Hospitals Trust, Gastroenterology, Newcastle upon Tyne, United Kingdom 2Newcastle University, Institute of Genetic Medicine, Newcastle upon Tyne, United Kingdom 3Newcastle University, Institute of Cellular Medicine, Newcastle upon Tyne, United Kingdom

P660: Prevalence and clinical course of cytomegalovirus colitis in Asian patients with acute exacerbation of ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Lim W.-C., Lin H.

Tan Tock Seng Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore

P661: Comparable clinical efficacy, safety and immunogenicity of infliximab biosimilar (CT-P13) after transition from reference infliximab (Remicade®) in children with established inflammatory bowel disease: a multi-centre prospective observational studyECCO '17 Barcelona
Year: 2017
Authors:

Sladek M.*1, Vultaggio A.2, Ghione S.3, Nencini F.2, Matucci A.2, Pratesi S.2, Zanieri F.4, Maggi P.M.2, Paci M.5, Ponanta-Gawron K.1, Kulig K.6, Wasilewska A.1, Lionetti P.7

1Jagiellonian University Medical College, Department of Pediatrics, Gastroenterology and Nutrition, Krakόw, Poland 2University of Florence, Centre of Research DENOTHE and Department of Experimental and Clinical Medicine, Florence, Italy 3Univeristy of Florence, Florence, Italy 4University of Florence, Florence, Italy 5Meyer Children's Hospital, Florence, Italy 6Univeristy Hospital in Krakow, Krakow, Poland 7University of Florence, Department of Neuroscience, Psychology, Drug Research and Child Health, Meyer Children's Hospital, Florence, Italy

P662: Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysisECCO '17 Barcelona
Year: 2017
Authors:

Paschos P.1,2, Katsoula A.2, Giouleme O.*2, Tsapas A.1,3

1Aristotle University, Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Thessaloniki, Greece 2Aristotle University, Second Propedeutic Medical Department, Thessaloniki, Greece 3University of Oxford, Harris Manchester College, Oxford, United Kingdom

P663: Switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: one year follow-up of a prospective observational cohort studyECCO '17 Barcelona
Year: 2017
Authors:

Smits L.*1, Grelack A.1, Drenth J.1, de Jong D.1, Boshuizen R.2, van Esch A.1, Derikx L.1, Hoentjen F.1

1Radboud university medical centre, Gastroenterology and Hepatology, Nijmegen, Netherlands 2Sanquin Diagnostic Services, Biologics Laboratory, Amsterdam, Netherlands

P664: The transitioning healthcare economy of IBD: changes in resource allocation over timeECCO '17 Barcelona
Year: 2017
Authors:

Spizzo P.

St Vincent's Hospital Melbourne, Victoria, Australia

P665: Unchanged infliximab serum concentrations after switching from the reference infliximab to the biosimilar CT-P13 in patients with quiescent Crohn's disease: a prospective studyECCO '17 Barcelona
Year: 2017
Authors:

Strik A.*1, van de Vrie W.2, van Megen Y.3, Bloemsaat-Minekus J.3, Rispens T.4, D'Haens G.1

1Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, Netherlands 2Albert Schweitzer Hospital, Department of Gastroenterology and Hepatology, Dordrecht, Netherlands 3Mundipharma Pharmaceuticals BV, Hoevelaken, Netherlands 4Academic Medical Center (AMC), Tytgat Institute for Intestinal and Liver Research, Amsterdam, Netherlands

P666: Short-term outcomes of adalimumab for patients with Crohn's disease and associated prognostic factors: a multicentre retrospective cohort studyECCO '17 Barcelona
Year: 2017
Authors:

Nasuno M.*1, Tanaka H.1, Miyakawa M.1, Motoya S.1, Ishii M.2, Shiotani A.2, Yamashita M.3, Itoh F.3, Tanuma T.4, Sakemi R.5, So S.5, Suzuki R.6, Yanagisawa H.7, Onodera K.8, Kaneto H.9, Nojima M.10, Nakase H.8

1Sapporo Kosei General Hospital, IBD Center, Sapporo, Japan 2Kawasaki Medical School, Department of Internal Medicine, Division of Gastroenterology, Kurashiki, Japan 3St. Marianna University School of Medicine, Division of Gastroenterology and Hepatology, Kawasaki, Japan 4Teine Keijinkai Hospital, Center for Gastroenterology, Sapporo, Japan 5Tobata Kyoritsu Hospital, Department of Gastroenterology, Kitakyusyu, Japan 6Hakodate Goryoukaku Hospital, Department of Gastroenterology, Hakodate, Japan 7Obihiro Kosei General Hospital, Department of Gastroenterology and Hepatology, Obihiro, Japan 8Sapporo Medical University, School of Medicine, Department of Gastroenterology and Hepatology, Sapporo, Japan 9Muroran City General Hospital, Department of Gastroenterology, Muroran, Japan 10The University of Tokyo, The Institute of Medical Science, Center for Translational Research, Tokyo, Japan

P667: Safety of anti-TNF treatment in liver transplant recipients – a meta-analysisECCO '17 Barcelona
Year: 2017
Authors:

Westerouen van Meeteren M.1, Inderson A.1, Hayee B.2, van der Meulen A.1, Altwegg R.3, van Hoek B.1, Pageaux G.-P.3, Stijnen T.4, Stein D.5, Maljaars J.*1

1LUMC, Department of Gastroenterology-Hepatology, Leiden, Netherlands 2King's College Hospital, Department of Gastroenterology, London, United Kingdom 3University Hospital of St. Eloi, Department of Hepatology and Gastroenterology, Montpellier, France 4LUMC, Department of Medical statistics, Leiden, Netherlands 5Medical College of Wisconsin, Division of Gastroenterology and Hepatology, Milwaukee, United States